Drug Discovery News: outbreak puts spotlight on antiviral drug discovery gaps

Drug Discovery News weekly rundown (May 2026) highlights how the MV Hondius cluster has exposed structural gaps in antiviral drug development for hantaviruses. Notes the absence of an approved antiviral (ribavirin showed no significant mortality reduction in meta-analysis) and the limited commercial incentive for pharma to invest in rare-pathogen therapeutics in the absence of biodefense funding.

Cases

—

Deaths

—

Author

—

Disease

hantavirus